UofL Health first in Kentucky to use new ‘Monarch’ technology for detecting lung cancer

Thousands of people die every year from lung cancer and Kentucky is at the top of the list for the number of people with the disease.



Monarch technology


© Provided by WLKY Louisville
Monarch technology

Now, doctors are hoping new technology at UoL Health Jewish Hospital will help change those statistics and save lives. The new technology is called the Monarch.


Sign up for our Newsletters

“So the Monarch is a robotic navigational bronchoscopy,” said Dr. Matthew Black, UofL Health Jewish Hospital.

Black describes it as a lighted camera allowing surgeons to see a patient’s airway and lungs. UofL Health Jewish Hospital is the first in Kentucky to use it to help detect lung cancer earlier.

Black, a thoracic surgeon, performed the first procedure in November.

“This technology allows us to get further into the peripheral lung which is where most lung cancers start and by utilizing this technology we can

Read More

Covid-19 Is derailing cancer clinical trials. Is new technology required to get them back on track?

Paper made silhouettes with one of them of orange color to stand out from the rest

The coronavirus pandemic has affected every aspect of American healthcare. Some have postponed medical, dental or vision appointments for themselves or family members out of fear of contracting the virus. Many providers have deferred nonessential visits to slow the pandemic’s spread and keep critical staff available to treat patients with Covid-19.

The clinical trial cycle is also experiencing significant disruption. One leading oncology practice publication notes that new cancer diagnoses are down 37% since the pandemic began, and IQVIA data shows that “22 million people postponed cancer screening tests and 80,000 patients delayed or missed diagnoses.” (IQVIA is an investor in Inteliquet, the company I lead as president and COO).

How do we ensure that the right patient can still access the right drug at the right time, at a time when many oncology clinical trials which would provide a much-needed treatment option have been delayed?

A Cancer Diagnosis Has

Read More

New tool to predict breast cancer recurrences

A new tool combining traditional pathology with machine learning could predict which breast cancer patients actually need surgery. The technology, reported in the November issue of American Journal of Physiology — Cell Physiology (vol. 319: C910-C921; https://doi.org/10.1152/ajpcell.00280.2020), could spare women from unnecessary treatments, reduce medical expenses, and lead to a new generation of drugs to stop breast cancer recurrences.

Ductal carcinoma in situ (DCIS) of the breast, an early form of disease also known as stage 0 breast cancer, is a diagnosis that only sometimes leads to invasive breast cancer. But only some patients need surgery, chemotherapy and/or radiotherapy, and the rest could be sent home. Predicting the outcomes of patients with early forms of cancer has been a major scientific problem for decades.

Professor Howard Petty and Ms. Alexandra Kraft, his research assistant, both of the University of Michigan, have just

Read More

More evidence that cellular ‘death by iron’ could be promising avenue of cancer treatment — ScienceDaily

If there is a silver lining in cancer’s chaotic biology, it’s that the same traits that give cancer cells a growth advantage often present opportunities for sabotaging them.

That’s the central idea behind a new research paper published November 23 in Proceedings of the National Academy of Sciences (PNAS) by Xuejun Jiang, a cell biologist in the Sloan Kettering Institute, and Craig Thompson, President and CEO of Memorial Sloan Kettering. They found that cancer cells often exhibit metabolic changes that make them vulnerable to a particular type of cell death called ferroptosis.

Ferroptosis — literally, death by iron — is often triggered by oxidative stress, the buildup in cells of free radicals and other corrosive chemicals that are byproducts of using oxygen to burn fuel for energy. But many cancer cells, which need abundant amounts of energy to grow and divide, have found a way around this problem.

“Genetic mutations

Read More

Can We Cure Cancer With Disruptive Technologies?

By Öykü Ilgar, SAP

Earlier this year, the Technical University of Munich (TUM) was named a winner of the SAP Innovation Awards for achieving a breakthrough in protein analysis on cancer research. Leveraging big data analytics, the team was able to make a major advancement in protein analysis: A team headed by Prof. Dr. Bernhard Küster succeeded to create a comprehensive map of proteins within the human body. Analyzing this data will help to fight deadly diseases more effectively with targeted treatments.

80% of the human proteome can be accessed “online”

“If we do understand, particularly in the context of diseases, how things work inside a cell, inside an organ, inside a human as a whole, we might better understand how we can tackle diseases,” said Prof. Dr. Bernhard Küster, Head of the Chair of Proteomics and Bioanalytics at the Technical University of Munich. “This has been a quest

Read More

Cancer Vaccines Market Insights, Size, Future Growth, Technology, Demand, Share, Competitive Analysis by Top Players and Forecasts to 2027

The MarketWatch News Department was not involved in the creation of this content.

Dec 01, 2020 (Market Insight Reports) —
Selbyville, Delaware, According to the report titled ‘Global Cancer Vaccines Market Size study, by Type, by Technology, by Indication (Cervical Cancer, Prostate Cancer, Others), by End-User (Pediatrics, Adults) and Regional Forecasts 2020-2027’, available with Market Study Report LLC, global cancer vaccines market was worth USD 4.2 billion in 2019 and is anticipated to record a 12.6% CAGR during 2020-2027.

Increasing investment & government funding for vaccine development, rising cognizance regarding cancer therapy, and growing number of cancer patients are the key factors driving the growth of global cancer vaccines market. As per International Agency for Research on Cancer (IARC), in 2018, about 18.1 million new cancer cases and 9.6 million cancer deaths were recorded worldwide. Moreover, approximately 27.5 million new cases of cancer, with nearly 16.3 million deaths from cancer

Read More

Telomere shortening protects against cancer — ScienceDaily

As time goes by, the tips of your chromosomes — called telomeres — become shorter. This process has long been viewed as an unwanted side-effect of aging, but a recent study shows it is in fact good for you.

“Telomeres protect the genetic material,” says Titia de Lange, Leon Hess Professor at Rockefeller. “The DNA in telomeres shortens when cells divide, eventually halting cell division when the telomere reserve is depleted.”

New results from de Lange’s lab provide the first evidence that telomere shortening helps prevent cancer in humans, likely because of its power to curtail cell division. Published in eLife, the findings were obtained by analyzing mutations in families with exceptional cancer histories, and they present the answer to a decades-old question about the relationship between telomeres and cancer.

A longstanding controversy

In stem cells, including those that generate eggs and sperm, telomeres are maintained by telomerase, an enzyme

Read More

Anixa Biosciences Announces Licensing Agreement with Cleveland Clinic for Ovarian Cancer Vaccine Technology

Anixa to Host a Conference Call Thursday, December 3, 2020, 1:15 p.m. PT to Discuss Program

SAN JOSE, Calif., Dec. 1, 2020 /PRNewswire/ — Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that it has entered into a license agreement with Cleveland Clinic for exclusive, world-wide rights to an innovative ovarian cancer vaccine technology. 


Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)

Cleveland Clinic immunologist Dr. Vincent Tuohy has been working on a method to vaccinate women against ovarian cancer and other gynecological malignancies.  This development-stage vaccine targets the extracellular domain of anti-mullerian hormone receptor 2 (AMHR2-ED), that appears in many types of ovarian cancer.  AMHR2-ED is one of several proteins identified by Dr. Tuohy as “retired” proteins.  While these proteins are necessary during the early stages of life, they are “retired” as a person ages, and are no longer expressed, or made at

Read More

A machine learning model developed in Finland can help us treat cancer more effectively — ScienceDaily

When healthcare professionals treat patients suffering from advanced cancers, they usually need to use a combination of different therapies. In addition to cancer surgery, the patients are often treated with radiation therapy, medication, or both.

Medication can be combined, with different drugs acting on different cancer cells. Combinatorial drug therapies often improve the effectiveness of the treatment and can reduce the harmful side-effects if the dosage of individual drugs can be reduced. However, experimental screening of drug combinations is very slow and expensive, and therefore, often fails to discover the full benefits of combination therapy. With the help of a new machine learning method, one could identify best combinations to selectively kill cancer cells with specific genetic or functional makeup.

Researchers at Aalto University, University of Helsinki and the University of Turku in Finland developed a machine learning model that accurately predicts how combinations of different cancer drugs kill various

Read More

Curiosity and Creativity Fuel Advancements in Pancreatic Cancer Research

WOODBURY, N.Y., Nov. 30, 2020 /PRNewswire/ — From cancer to COVID to computer technology, innovation often begins as a spark of creativity lit by a researcher’s curiosity. Whether viewing existing research through a different lens or bringing a new perspective to an unaddressed problem, what happens in the lab depends a lot on the individual researcher puzzling over data.

Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8622452-lustgarten-foundation-pancreatic-cancer-research-labs-and-blog/

Scientific research—when seen only from a distance, on television or the news—can appear sterile, antiseptic, formulaic. Goggled workers in white coats wielding pipettes offer us only a tiny glimpse of the creativity it takes to tackle tough challenges like pancreatic cancer. Speak to the young, ambitious, driven researchers working on this disease and you’ll hear inspiring ways they find and nurture the spark they need to tackle such a demanding project.

For Tobiloba Oni, working at Cold Spring Harbor Laboratory, in suburban

Read More